Oberonheimer raised Moderna's target price from $163 to $179 and maintained an 'outperform' rating. Analysts said that Moderna's newly approved respiratory syncytial virus (RSV) vaccine may enjoy higher penetration than expected when entering the US market, despite two experienced competitors, GlaxoSmithKline and Pfizer, already in the market. At the end of last month, Moderna announced that it had received approval from the US Food and Drug Administration to begin using mResvia vaccine in adults aged 60 and above. They believe that the RSV vaccine market is large enough and there is enough space to accommodate another company.
大行评级｜奥本海默：上调Moderna目标价至179美元 指其RSV疫苗仍有充足的机会
Bank rating: O'Brienheimer raised the target price of Moderna to $179, indicating that its RSV vaccine still has ample opportunities.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.